Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Study Of PF-04518600 In Patients With Select Advanced Solid Tumors

Complete title: A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTEDLOCALLY ADVANCED OR METASTATIC CARCINOMAS

Research Study Number 20150061
 
Principal Investigator John Thompson, MD
 
Phase I

Research Study Description

To assess the safety and tolerability at increasing dose levels of PF-04518600 in patients with advanced or metastatic hepatocellular carcinoma (HCC), melanoma, clear cell renal cell carcinoma (RCC) or squamous cell head and neck cancer (SCCHN) in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20150061
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Gastrointestinal Cancer; Head and Neck Cancer; Kidney Cancer; Liver Cancer; Melanoma; Renal Cancer; Solid Tumors; Neoplasms; Urogenital Neoplasms; Urologic Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials